title: IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism.
abstract: Parkinsonism is most of the time caused by idiopathic Parkinson's disease (IPD). Considering the differences in therapeutic response and prognosis, in vivo discrimination between IPD and "parkinsonism-plus" syndromes is important. Recently, ligands have become available for imaging the pre- and postsynaptic dopaminergic system by Single Photon Emission Computed Tomography (SPECT). Visualization of postsynaptic D2 dopamine receptors using 123I-iodobenzamide (123I-IBZM) may contribute to the differential diagnosis between IPD and "parkinsonism-plus" syndromes as IPD is a pure presynaptic disease. Imaging of the presynaptic dopamine transporters using [123I] beta-CIT (2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane) may be used as a diagnostic technique. Early disease detection in subjects suspected to be at risk for developing IPD has become possible using [123I] beta-CIT or other ligands for the dopamine transporter. Furthermore, with SPECT one is probably able to monitor in an objective way the efficacy of new pharmacological therapies.
authors.affiliation: Graduate School Neurosciences, Department of Neurology, Academisch Ziekenhuis VU Amsterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Tissingh
authors.forename: J
authors.initials: J
authors.lastname: Booij
authors.forename: A
authors.initials: A
authors.lastname: Winogrodzka
authors.forename: E A
authors.initials: EA
authors.lastname: van Royen
authors.forename: E C
authors.initials: EC
authors.lastname: Wolters
mesh_terms: D001549:Benzamides; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D003042:Cocaine / Q000031:analogs & derivatives*; D003937:Diagnosis, Differential; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D006801:Humans; D007457:Iodine Radioisotopes; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D010302:Parkinson Disease, Secondary / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000378:metabolism*; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000032:analysis / Q000378:metabolism; D012307:Risk Factors; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001549:Benzamides; D018492:Dopamine Antagonists; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003042:Cocaine; D004298:Dopamine